Nanox Signs Distribution Agreement with Associated X-Ray Imaging to Expand Nanox.ARC Adoption Across New England
Nanox adds a New England distributor for Nanox.ARC, extending its U.S. channel strategy and reach into outpatient and community imaging sites.
Rhea-AI Summary
Nano-X Imaging (NNOX) announced that its U.S. subsidiary Nanox Impact has signed a distribution agreement with New England-based Associated X-Ray Imaging to expand deployment of the FDA-cleared Nanox.ARC system across the region.
Associated X-Ray Imaging will market, distribute, and support the Nanox.ARC, a multisource 3D digital tomosynthesis system, using its established sales and service infrastructure. The collaboration targets broader access to advanced 3D imaging in outpatient and community-based clinical settings and fits into Nanox’s U.S. channel partner strategy to build a diversified regional distribution network.
Positive
- New distribution agreement adds Associated X-Ray Imaging as Nanox.ARC channel partner across New England
- Leverages established network of hospitals, imaging centers, and specialty clinics served by Associated X-Ray Imaging
- Supports U.S. commercial execution by targeting outpatient and community-based clinical settings for Nanox.ARC adoption
Negative
- None.
Market Reaction – NNOX
Following this news, NNOX has gained 2.43%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.73. Trading volume is exceptionally heavy at 18.7x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 25 | Earnings date notice | Neutral | +1.5% | Scheduled second-quarter 2026 results and conference call for September 9 |
| Aug 18 | AI reseller agreement | Positive | -5.0% | Exclusive United Kingdom commercialization agreement for HealthOST |
| Aug 10 | AI technology update | Positive | +0.5% | Optimized medical imaging AI framework for Intel Core Ultra processors |
| Aug 6 | Registered direct offering | Negative | +2.0% | Priced an 8 million dollar registered direct offering with accompanying warrants |
| Jul 7 | Clinical data presentation | Neutral | -6.1% | Announced planned presentation of new cardiac imaging data at SCCT 2026 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive AI and clinical announcements produced mixed outcomes, including a 5% decline on August 18 and a 0.47% gain on August 10.
Key Terms
digital tomosynthesis technical
fda-cleared regulatory
teleradiology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider
PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-ray, MRI, and CT systems, to support deployment of the Nanox.ARC across the region.
Under the agreement, Associated X-Ray Imaging will market, distribute, and support the Nanox.ARC, an FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its established regional presence and service infrastructure across New England. The collaboration is expected to support Nanox’s ongoing U.S. commercial execution by expanding access to advanced 3D imaging within additional outpatient and community-based clinical settings.
Associated X-Ray Imaging has been serving healthcare providers across New England for decades, supplying and servicing a broad range of diagnostic imaging technologies for hospitals, imaging centers, and specialty clinics.
“We continue to build our U.S. commercial footprint through focused regional distribution partnerships that are aligned with our deployment strategy,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “Associated X-Ray Imaging brings long-standing customer relationships, strong technical expertise, and a deep understanding of the New England imaging market. This partnership supports our efforts to expand measured adoption of the Nanox.ARC across additional clinical environments.”
“We are pleased to partner with Nanox and add the Nanox.ARC to our imaging portfolio,” said John Olenio, Owner, Founder and Chief Executive Officer of Associated X-Ray Imaging Corp. “We believe the Nanox.ARC offers a compelling approach to 3D imaging that aligns with our focus on providing practical diagnostic solutions supported by reliable service across New England.”
This agreement represents another step in Nanox’s U.S. channel partner strategy, as the Company continues to expand a diversified distribution network to support commercial deployment of the Nanox.ARC across targeted U.S. regions.
About Associated X-Ray Imaging Corp
Founded in 1975, Associated X-Ray Imaging Corp. is a New England-based provider of medical imaging equipment, service, and supplies. The company supports hospitals, imaging centers, and specialty clinics with diagnostic imaging technologies across multiple modalities, including X-ray, MRI, and CT, supported by a regional sales and service organization. For more information, visit www.associatedxray.com
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
